Published in Neuropsychopharmacology on January 01, 2010
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg Med Chem Lett (2011) 1.03
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs (2015) 0.90
Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. Biol Psychiatry (2016) 0.83
PharmGKB summary: dopamine receptor D2. Pharmacogenet Genomics (2011) 0.78
Bioluminescence-based high-throughput screen identifies pharmacological agents that target neurotransmitter signaling in small cell lung carcinoma. PLoS One (2011) 0.78
Sensing conformational changes in metabotropic glutamate receptors. Proc Natl Acad Sci U S A (2013) 0.76
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci (2007) 2.35
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol (2009) 1.44
Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther (2002) 1.25
Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol (1997) 0.99
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des (2010) 1.24
Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J Pharm Pharmacol (2013) 0.79